Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pharmasset gains on R7128 data

Pharmasset (NASDAQ:VRUS) gained $6.25 (45%) to $20.24 on Monday after preliminary data from

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE